Company intelligence / Profile preview

FibroFind

Newcastle upon Tyne, England, United Kingdomfibrofind.com ↗

Ownership: Private
Development stage: Other

Overview

FibroFind has developed and commercialized a proprietary human ex vivo tissue slice platform that enables pharmaceutical companies to test antifibrotic drug candidates in physiologically relevant human organ models. This approach offers more predictive data than traditional animal models, supporting better decision-making before clinical trials. The company has rapidly expanded its client base globally and was acquired by Vespa Capital in April/May 2025 to accelerate growth and broaden its scientific reach.

Therapeutic areas: NephrologyRare DiseasesGastroenterologyPulmonology
Modalities: Ex vivo tissue model platform (human precision-cut tissue slices)
Industry: Drug Discovery Services

Partnerships

Pharmaceutical and biotech companies as clients (>65 as of April/May 2025)

Beyond the preview

Go deeper on FibroFind.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FibroFind.

Explore the full profile